Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer.
Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer.
复制标题
DOI：
10.1038/s41598-018-23848-8
复制
发表时间：
2018-04-04
影响因子：
4.6
通讯作者：
Koshiol J
中科院分区：
文献类型：
--
作者：
Liu Z;Kemp TJ;Gao YT;Corbel A;McGee EE;Roa JC;Wang B;Araya JC;Shen MC;Rashid A;Hsing AW;Hildesheim A;Ferreccio C;Pfeiffer RM;Pinto LA;Koshiol J
尽管炎症是胆囊癌（GBC）发展和增殖的核心，但尚未有研究系统地研究循环炎症蛋白和患者生存。我们的目的是检查炎症蛋白的循环水平是否与这些患者的全因死亡率相关。我们招募了1997年至2001年在上海进行的一项基于人群的研究中的134例新诊断GBC患者，以及2012年至2013年在智利进行的一组独立的35例患者。采用校正协变量的考克斯比例风险回归模型，通过49种炎性蛋白（四分位数）的血清水平评价死亡的风险比（HR）。在49种可评估的蛋白质中，有8种与总生存率显著相关。其中7例与生存率较差相关，而肿瘤坏死因子相关凋亡诱导配体（TRAIL）水平最高与生存率增加相关（HR = 0.26，95% CI = 0.14，0.47）。在早期和晚期GBC之间观察到的关联程度没有实质性差异。在七种蛋白质中，有五种在智利患者中得到了验证。减少炎症和靶向与生存率增加相关的途径可能会改善GBC的结果。使用TRAIL相关抗癌药物治疗GBC的潜力值得进一步研究。
Although inflammation is central to gallbladder cancer (GBC) development and proliferation, no study has systematically investigated circulating inflammatory proteins and patient survival. We aimed to examine whether the circulating levels of inflammatory proteins is associated with all-cause mortality among such patients. We recruited 134 patients with newly diagnosed with GBC from 1997 to 2001 in a population-based study in Shanghai and an independent set of 35 patients from 2012 to 2013 in Chile. Cox proportional hazards regression models adjusted for covariates were used to evaluate the hazard ratios (HRs) for death by serum levels of 49 inflammatory proteins (quartiles). Of 49 evaluable proteins, eight were significantly associated with overall survival. Seven were associated with a poorer survival, while the highest levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were associated with an increase in survival (HR = 0.26, 95% CI = 0.14, 0.47). No substantial difference in the magnitude of the association was observed between early- and late-stages of GBC. Of seven proteins, five were validated in the patients from Chile. Reducing inflammation and targeting pathways associated with increased survival might improve GBC outcomes. The potential for using a TRAIL-related anticancer drug for GBC treatment merits further investigation.
登录
查看更多内容
DOI：
10.1186/bcr2903
发表时间：
2011-06-21
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Kodera Y;Katanasaka Y;Kitamura Y;Tsuda H;Nishio K;Tamura T;Koizumi F
通讯作者：
Koizumi F
影响因子：
8.8
作者：
Hsing, A. W.;Gao, Y-T;Han, T-Q;Rashid, A.;Sakoda, L. C.;Wang, B-S;Shen, M-C;Zhang, B-H;Niwa, S.;Chen, J.;Fraumeni, J. F., Jr.
通讯作者：
Fraumeni, J. F., Jr.
影响因子：
8
作者：
Dimberg LY;Anderson CK;Camidge R;Behbakht K;Thorburn A;Ford HL
通讯作者：
Ford HL
1973-2010年上海城区癌症发病率：最新趋势和年龄-时期-队列效应
影响因子：
3.8
作者：
Bao PP;Zheng Y;Wu CX;Huang ZZ;Gao YT;Jin F;Xiang YB;Zhong WJ;Lu W;Wu F
通讯作者：
Wu F
影响因子：
120.7
作者：
Ghali, WA;Quan, HD;Knudtson, ML
通讯作者：
Knudtson, ML